Serif Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare price transparency API and data infrastructure for CMS compliance; $1.2M monthly revenue at 8 people from YC W21 normalizing hospital and insurer rate files for health plans and employers.
About
Serif Health is a Los Angeles-based healthcare price transparency infrastructure company providing APIs and data products that power hospital rate search, insurance network intelligence, and CMS compliance analytics — helping health plans, self-funded employers, TPAs (third-party administrators), and data analytics firms navigate the complex requirements of the CMS Price Transparency and Transparency in Coverage rules that mandate hospitals and insurers to publish machine-readable pricing files. Founded in 2020 and a Y Combinator W21 graduate, Serif raised $2.52 million from 1984 Ventures and angel investors, achieving $1.2 million in monthly revenue as of December 2024 with an 8-person team.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.